Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma
A Ingels, R Campi, U Capitanio, D Amparore… - Nature Reviews …, 2022 - nature.com
Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …
Management of metastatic clear cell renal cell carcinoma: ASCO guideline
WK Rathmell, RB Rumble… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …
French AFU Cancer Committee Guidelines-update 2022-2024: management of kidney cancer
P Bigot, P Barthelemy, R Boissier, ZE Khene… - Progrès en Urologie, 2022 - Elsevier
Aim To update the recommendations for the management of kidney cancers. Methods A
systematic review of the literature was conducted from 2015 to 2022. The most relevant …
systematic review of the literature was conducted from 2015 to 2022. The most relevant …
The selection for cytoreductive nephrectomy (SCREEN) score: improving surgical risk stratification by integrating common radiographic features
Background Careful patient selection is critical when considering cytoreductive nephrectomy
(CN) for metastatic renal cell carcinoma (mRCC) but few studies have investigated the …
(CN) for metastatic renal cell carcinoma (mRCC) but few studies have investigated the …
Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC
A Das, DD Shapiro, JK Craig, EJ Abel - Nature Reviews Urology, 2023 - nature.com
Cytoreductive nephrectomy became accepted as standard of care for selected patients with
metastatic renal cell carcinoma (mRCC) because of improved survival observed in patients …
metastatic renal cell carcinoma (mRCC) because of improved survival observed in patients …
Cytoreductive nephrectomy and metastatic renal cell carcinoma: state of the art and future perspectives
L Napolitano, C Manfredi, L Cirillo, GM Fusco… - Medicina, 2023 - mdpi.com
In the past decades, several treatments have been proposed for the management of
metastatic renal cell carcinoma (mRCC). Among these, cytoreductive nephrectomy (CN) …
metastatic renal cell carcinoma (mRCC). Among these, cytoreductive nephrectomy (CN) …
Pathological outcomes of patients with advanced renal cell carcinoma who receive nephrectomy following immunotherapy
Background Even though cytoreductive nephrectomy (CN) was once the standard of care for
patients with advanced renal cell carcinoma (RCC), its role in treatment has not been well …
patients with advanced renal cell carcinoma (RCC), its role in treatment has not been well …
The evolving landscape of cytoreductive nephrectomy in metastatic renal cell carcinoma
H Studentova, M Spisarova, A Kopova, A Zemankova… - Cancers, 2023 - mdpi.com
Simple Summary For a significant period of time, the removal of the primary tumor termed
cytoreductive nephrectomy has been considered the standard of care in patients with …
cytoreductive nephrectomy has been considered the standard of care in patients with …
Treatment options for de novo metastatic clear-cell renal cell carcinoma: current recommendations and future insights
D Benamran, L Albiges, A Bex, G Giannarini… - European Urology …, 2022 - Elsevier
This clinical case–based discussion focuses on a 73-yr-old man diagnosed with
intermediate-risk oligometastatic clear-cell renal cell carcinoma (RCC) and treated with …
intermediate-risk oligometastatic clear-cell renal cell carcinoma (RCC) and treated with …
[HTML][HTML] Cytoreductive nephrectomy in the age of immunotherapy-based combination treatment
SH Song, S Lee - Investigative and clinical urology, 2023 - ncbi.nlm.nih.gov
Renal cell carcinoma (RCC) displays a wide spectrum of oncological prognosis and clinical
behavior, and is noted for its generally poor outcome in metastatic settings. However, the …
behavior, and is noted for its generally poor outcome in metastatic settings. However, the …